- Home
- WFRD vs ALKS Comparison
WFRD vs ALKS Comparison
Compare WFRD & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WFRD
- ALKS
- Stock Information
- Founded
- WFRD 1941
- ALKS 1987
- Country
- WFRD United States
- ALKS Ireland
- Employees
- WFRD N/A
- ALKS N/A
- Industry
- WFRD Metal Fabrications
- ALKS Biotechnology: Pharmaceutical Preparations
- Sector
- WFRD Industrials
- ALKS Health Care
- Exchange
- WFRD Nasdaq
- ALKS Nasdaq
- Market Cap
- WFRD 5.4B
- ALKS 4.7B
- IPO Year
- WFRD N/A
- ALKS 1991
- Fundamental
- Price
- WFRD $73.26
- ALKS $30.10
- Analyst Decision
- WFRD Strong Buy
- ALKS Buy
- Analyst Count
- WFRD 8
- ALKS 11
- Target Price
- WFRD $140.50
- ALKS $36.00
- AVG Volume (30 Days)
- WFRD 968.7K
- ALKS 1.3M
- Earning Date
- WFRD 02-05-2025
- ALKS 02-13-2025
- Dividend Yield
- WFRD 1.36%
- ALKS N/A
- EPS Growth
- WFRD 51.37
- ALKS 55.25
- EPS
- WFRD 7.14
- ALKS 1.97
- Revenue
- WFRD $5,534,000,000.00
- ALKS $1,505,121,000.00
- Revenue This Year
- WFRD $10.75
- ALKS N/A
- Revenue Next Year
- WFRD $0.79
- ALKS N/A
- P/E Ratio
- WFRD $10.26
- ALKS $15.28
- Revenue Growth
- WFRD 11.08
- ALKS N/A
- 52 Week Low
- WFRD $66.23
- ALKS $22.90
- 52 Week High
- WFRD $135.00
- ALKS $32.88
- Technical
- Relative Strength Index (RSI)
- WFRD 50.12
- ALKS 59.48
- Support Level
- WFRD $68.46
- ALKS $28.28
- Resistance Level
- WFRD $74.90
- ALKS $29.36
- Average True Range (ATR)
- WFRD 2.79
- ALKS 0.69
- MACD
- WFRD 0.68
- ALKS 0.12
- Stochastic Oscillator
- WFRD 70.25
- ALKS 97.96
About WFRD Weatherford International plc
Weatherford International provides diversified oilfield services across international markets for an array of oilfield types. The firm is a global market leader in artificial lift and tubular running services. Other key product lines include cementing products, directional drilling, and wireline evaluation.
About ALKS Alkermes plc
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.